Partner with us for cell line and strain development, manufacturability assessments, cell banking and toxicology material generation. Let us guide your path to IND/IMPD submission.
Partner with us for process validation and process performance qualification. Leverage our CMC and regulatory services for your BLA/MAA submission and experience our reliability.
HILLERØD, DENMARK, November 5, 2024 – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, proudly announces that the first phase of its expansion at the Hillerød site is ready to bring the new production capacity into operation.
HOLLY SPRINGS, N.C., November 4, 2024, FUJIFILM Diosynth Biotechnologies, a world leading CDMO, today announced that TG Therapeutics, Inc. (NASDAQ: TGTX) has committed to a multi-year manufacturing supply agreement for BRIUMVI® (ublitiximab-xiiy), its U.S. FDA-approved therapeutic for relapsing forms of multiple sclerosis (RMS).
August 20, 2024 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today hosted a celebration for the opening of its microbial fermentation manufacturing facility in Billingham.